Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Board fully replaced NBB
No director from three years ago is still active according to annual account 2025.
Financials
Financial year 2025
Telix Pharmaceuticals (Belgium) from Seneffe, company number BE0695832765, closed financial year 2025 with a result of € -54,903 after tax. For that financial year Telix Pharmaceuticals (Belgium) recorded revenue of € 14.9 million and equity of € 515,466. Compared with financial year 2024, the result moved from € 30,074 to € -54,903. The company made a loss. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 31, 2026.
€ 515,466
▼ 10% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -54,903
▼ still € 30,074 profit in 2024
Profit after tax over the fiscal year.
€ 1.9 million
▲ 282% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 151,647.
People and assets in 2025
51
▲ 16.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 7.9 million
▲ 89% vs 2024
€ 155,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 694,535
▲ € 676,893 vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 14.8 million
▼ 2% vs 2024
€ 7.2 million is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 2.6 million
▲ 19% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 129 days on average.
€ 2.7 million
▲ 132% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | - | - | € 8,629,300 | € 14,873,793 | ▲ 72% |
| Gross margin | € -2,195,019 | € 3,023,129 | - | - | |
| Profit after taxes | € 64,209 | € -1,008 | € 30,074 | € -54,903 | ▼ € 84,977 |
| Equity | € 151,865 | € 540,295 | € 570,369 | € 515,466 | ▼ 10% |
| Total debts | € 3,487,354 | € 17,688,512 | € 39,988,699 | € 49,672,715 | ▲ 24% |
| Cash | € 27,472 | € 2,636,610 | € 497,986 | € 1,900,383 | ▲ 282% |
| Land & buildings | € 1 | € 1 | € 1 | € 13,295,668 | ▲ € 13.3 million |
| Retained profit | € 139,465 | € 176,477 | € 206,551 | € 151,647 | ▼ 27% |
| Bank debt | € 0 | € 5,940,797 | € 15,100,669 | € 14,794,379 | ▼ 2% |
| Balance sheet total | € 6,866,639 | € 21,870,887 | € 47,477,228 | € 57,106,341 | ▲ 20% |
| Employees (FTE) | 1.7 | 25.2 | 34.9 | 51 | ▲ 16.1 |
Key figures of Telix Pharmaceuticals (Belgium), fiscal years 2021 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Telix Pharmaceuticals (Belgium)?
What happened at Telix Pharmaceuticals (Belgium) in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Ortiz Raphael stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 54,903 (▼ € 84,977 vs 2024). Source: NBB ↗
- Caroline Defraiteur became a director. NBB
- Ortiz Raphael became a director. NBB
- New establishment in Seneffe. KBO
- Start of the company according to the CBE. KBO
In short
From € 64,209 profit in 2021 to € 54,903 loss in 2025.
Paid € 339,658 in corporate taxes since 2021.
Best year ever: 2021, with € 64,209 profit.
On average € 120,000 of value added per employee in 2023.
A new publication or filing at Telix Pharmaceuticals (Belgium)? We notify you, reason included.
Follow Telix Pharmaceuticals (Belgium)Databakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Telix Pharmaceuticals (Belgium) is Caroline Defraiteur. The shares are held by Telix International Pty Ltd Autre (100%).
Directors
According to the 2025 annual accounts
Caroline Defraiteur
Director
since 2025
Ortiz Raphael
Director
since 2023 · until 2029
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue Jules Bordet 55
7180 Seneffe
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0695.832.765
- VAT number
- BE 0695.832.765
- Registered office
- Rue Jules Bordet 55, 7180 Seneffe
- Names & denominations
- Telix Pharmaceuticals (Belgium)
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 9 May 2018
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Vervaardiging van overige farmaceutische producten
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Vervaardiging van geneesmiddelen